MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4295-4300

  Yoshida, Motofumi ^a   Maehara, Yoshihiko ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; DOXORUBICIN; SOBUZOXANE;

ACUTE TOXICITY; ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; CARCINOMA CELL; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIGESTIVE SYSTEM; DOXORUBICIN; FEMALE; HUMANS; LETHAL DOSE 50; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PIPERAZINES; PRODRUGS; RAZOXANE; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0033397898     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Narita, T., Yaguchi, S., Komatsu, T., Takase, M., and Hoshino, A. Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models. Cancer Chemother. Pharmacol., 26: 193-197, 1990.
2. Narita, T., Koide, Y., Yaguchi, S., Kimura, S., Izumisawa, Y., Takase, M., Inaba, M., and Tsukagoshi, S. Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models. Cancer Chemother. Pharmacol., 28: 235-240, 1991.
3. Furue, H., Niitani, H., Nakao, I., Hoshino, A., Hasegawa, K., Tsukagoshi, S., and Fujita, H. Phase I study of MST-16. Jpn. J. Cancer Chemother., 17: 1287-1294, 1990.
4. Masaoka, T., and Furue, H. MST-16 for the treatment of lymphoma. J. Cancer Res. Clin. Oncol., 116 (Suppl. Part I): 607, 1990.
5. Ohno, R., Yamada, K., Hirano, M., Shirakawa, S., Tanaka, M., Oguri, T., Kodera, Y., Mitomo, Y., Ikeda, Y., Yokomaku, S., Kamiya, O., Kobayashi, M., Saito, H., and Kimura, K. Phase II Study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine). J. Natl. Cancer Inst., 84: 435-438, 1992.
6. Ohno, R., Masaoka, T., Shirakawa, S., Sakamoto, S., Hirano, M., Hanada, S., Yasunaga, K., Yokomaku, S., Kitomo, Y., Nagai, K., Yamada, K., and Furu, H. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). Cancer (Phila.), 71: 2217-2221, 1993.
7. Brubaker, L. H., Vogel, C., Einhorn, L. H., and Birch, R. Treatment of advanced adenocarcinoma of kidney with ICRF-187: a Southeastern Cancer Study Group trial. Cancer Treat. Rep., 70: 915-916, 1986.
8. Creaven, P. J., Allen, L. M., and Alford, D. A. The bioavailability in man of ICRF-159, a new oral antineoplastic agent. J. Pharm. Pharmacol., 27: 914-918, 1975.
9. Wheeler, R. H., Bricker, L. J., Natale, R. B., and Baker, S. R. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck. Cancer Treat. Rep., 68: 427-428, 1984.
10. Alderton, P. M., Gross, J., and Green, M. D. Comparative study of doxorubicin, mitoxantron, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res., 52: 194-201, 1992.
11. Dardir, M., Herman, E. H., and Ferrans, V. J. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol., 23: 269-275, 1989.
12. Herman, E. H., and Ferrans, V. J. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin toxicity in rabbits. Cancer Chemother. Pharmacol., 16: 102-106, 1986.
13. Herman, E. H., Ferrans, V. J., Young, R. S. K., and Hamlin, R. L. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res., 48: 6918-6925, 1988.
14. Perkins, W. E., Schroeder, R. L., Carrano, R. A., and Imondi, A. R. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. Br. J. Cancer, 46: 662-667, 1982.
15. Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., Wernz, J., Feit, F., Slater, W., Blum, R., and Muggia, F. M. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med., 319: 745-752, 1988.
16. Speyer, J. L., Green, M. D., Sanger, J., Zeleniuch-Jacquotte, A., Kramer, E., Rey, M., Wernz, J. C., Blum, R. H., Hochster, H., Meyers, M., and Muggia, F. M. A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat. Rev., 17: 161-163, 1990.
17. Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M., Sanger, J., Kramer, E., Ferrans, V., Hochster, H., Meyers, M., Blum, R. H., Feit, F., Attubato, M., Burrows, W., and Muggia, F. M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol., 10: 117-127, 1992.
18. Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Jr., Von Hoff, A. L., Rosencweig, M., and Muggia, F. M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Int. Med., 91: 710-717, 1979.
19. Kano, Y., Narita, T., Suzuki, K., Akutsu, M., Suda, K., Sakamoto, S., and Miura, Y. The effects of ICRF-154 in combination with other anticancer agents in vitro. Br. J. Cancer, 66: 281-286, 1992.
20. Tanaka, Y., Eda, H., Fujimoto, K., Tanaka, T., Ishikawa, T., and Ishitsuka, H. Anticachectic activity of 5́-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res., 50: 4528-4532, 1990.
21. Yamada, Y., Yoshida, T., Hayashi, K., Sekiya, T., Yokota, J., Hirohashi, S., Nakatani, K., Nakano, H., Sugimura, T., and Terada, M. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res., 51: 5800-5805, 1991.
22. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 52: 589-601, 1988.
23. Maehara, Y., Anai, H., Kusumoto, H., and Sugimachi, K. Poorly differentiated human gastric carcinoma is more sensitive to antitumor drugs than is well differentiated carcinoma. Eur. J. Surg. Oncol., 13: 203-206, 1987.
24. Chou, T-C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
25. Chou, T-C., and Talalay, P. Applications of the median effect principle for the assessment of low-dose risk carcinogens and the quantitation of synergism and antagonism of chemotherapeutic agents. In: K. R. Harrap, and T. A. Connors (eds.), New Avenues in Developmental Cancer Chemotherapy, pp. 37-64. New York: Academic, 1987.
26. Wadler, S., Green, M. D., and Muggia, F. M. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) against the murine sarcoma S180 cell line. Cancer Res., 46: 1176-1181, 1986.
27. Monti, E., and Sinha, B. K. Potenciation of doxorubicin cytotoxicity by (+)-1,2-bis-3,5-dioxopiperazine-1-yl)propane (ICRF-187) in human leukemic HL-60 cells. Cancer Commun., 2: 145-149, 1990.
28. Wadler, S., Green, M. D., Basch, R., and Muggia, F. M. Lethal and sublethal effects of the bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187), on murine sarcoma S180 in vitro. Biochem. Pharmacol., 36: 1495-1501, 1987.
29. Ishida, Y., Miki, T., Narita, T., Yui, R., Sato, M., Utsumi, R. K., Tanabe, K., and Andoh, T. Inhibition of topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res., 51: 4909-4916, 1991.
30. Tanabe, K., Ikegami, Y., and Andoh, T. Inhibition of topoisomerase II by antitumor agents bis(2,6-piperazine) derivatives. Cancer Res., 51: 4903-4908, 1991.
31. Woodman, R. J., Cysyk, R. L., Gang, M., and Venditti, J. M. Enhancement of the effect of daunorubicin (NSC-82151) or Adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Cancer Chemother. Rep., 59: 689-695, 1975.
32. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. Y., Pfeffer, M. R., Crawford, J. W., and Frei, E. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (Washington DC), 247: 1457-1461, 1990.
33. Balazsovits, J. A. E., Mayer, L. D., Bally, M. B., Cullis, P. R., McDonell, M., Ginsberg, R. S., and Falk, R. E. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother. Pharmacol., 23: 81-86, 1989.
34. Villani, F., Manzotti, C., Mella, M., Monti, E., Savi, G., and Zunnino, F. Effect of amrinone on anthracycline-induced lethal and cardiac toxicity in mice and rats. Med. Oncol. Tumor Pharmacother., 7: 227-232, 1990.
35. Baba, H., Stephens, L. C., Strebel, F. R., Siddik, Z. H., Newman, R. A., Ohno, S., and Bull, J. M. C. Protective effect of ICRF-187 against normal tissue injury induced by Adriamycin in combination with whole body hyperthermia. Cancer Res., 51: 3568-3577, 1991.
36. Herman, E., Ardalan, B., Bier, C., Waravdekar, V., and Krop, S. Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat. Rep., 63: 89-92, 1979.
37. Hashinoff, B. B. The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) its hydrolysis product (ICRF-198) and other chelating agents with the Fe(III) and Cu(II) complexes of Adriamycin. Agents Actions, 26: 378-385, 1989.
38. Sobol, M. M., Amiet, R. G., and Green, M. D. In vitro evidence for direct complexation of ADR-529/ICRF-187′(+)-1,2-bis-(3,5-dioxo-piperazine-1-yl)propane onto an existing ferric-anthracycline complex. Mol. Pharmacol., 41: 8-17, 1992.
39. Bristow, M. R., Billingham, M. E., Masson, J. W., and Daniels, J. R. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat. Rep., 62: 873-878, 1978.
40. Lefrak, E. A., Pitha, J., Rosenheim, S., O'Bryan, R. M., Burgess, M. A., and Gottlieb, J. A. Adriamycin (NSC123127) cardiomyopathy. Cancer Chemother. Rep., 6: 203-208, 1975.